Results 111 to 120 of about 742,291 (286)

A Living Multi‐Omics PDX Biobank of High‐Risk Sarcomas Reveals ecDNA‐Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology

Advanced Science, EarlyView.
A living multi‐omics sarcoma PDX biobank is enriched for high‐risk disease and preserves key patient tumor features at histopathological and molecular levels. Integrated profiling reveals ecDNA‐driven oncogene amplification in osteosarcoma and preferential retention of ecDNA during PDX evolution.
Weisong Zhao, Zhiwei Cheng, Kai Tian, Mengxiong Sun, Zhuoying Wang, Ming Jiao, Jens Luebeck, Kaiyuan Zhu, Xiao Zhang, Dongqing Zuo, Hongsheng Wang, Chongren Wang, Jiakang Shen, Xiaojun Ma, Gangyang Wang, Zongyi Wang, Jing Han, Kaiyuan Liu, Haoran Mu, Weiqi Ma, Yongyong Ren, Shibing Guo, Huangxin Tu, Lingfeng Yu, Yining Tao, Yu Lv, Hui Lu, Owen S. Chapman, Rishaan Kenkre, Lukas Chavez, Zhengdong Cai, Yuqin Yang, Wei Sun, Yafei Jiang, Yingqi Hua   +34 more
wiley   +1 more source

Disabling COMPASS Promoter Licensing Shifts HDAC‐Inhibited Gastric Cancer Toward Sustained Transcriptional Suppression During Recovery

Advanced Science, EarlyView.
Combined inhibition of the WDR5 WIN pocket and HDAC activity converts SAHA‐induced hyperacetylation into a promoter state with reduced WDR5–COMPASS association and H3K4me3. MYC/E2F‐linked nascent transcription and biosynthetic recovery are suppressed, while apoptosis and senescence‐like features increase, resulting in sustained growth inhibition in ...
Jintian Song, Hui Yu, Jianping Jiang, Zhihui Jiang, Zhongshi Hong, Xu Zhang, Luchuan Chen, Shenghong Wei, Yi Wang   +8 more
wiley   +1 more source

PARP inhibitors as precision medicine for cancer treatment

, 2017
Personalized or precision medicine is an emerging treatment approach tailored to individuals or certain groups of patients based on their unique characteristics.
Hirohito Yamaguchi, Jennifer L. Hsu, Yi Du, Mien-Chie Hung   +3 more
core   +1 more source

Tubocapsenolide A Overcomes Oxaliplatin Resistance in Colorectal Cancer by Targeting PLK1 to Impair CEP55–ESCRT‐Associated Vesicular Damage Clearance

Advanced Science, EarlyView.
Oxaliplatin‐resistant colorectal cancer cells utilize a previously unappreciated PLK1‐CEP55‐ESCRT‐driven vesicular extrusion mechanism to clear L‐OHP‐induced cellular damage. The natural withanolide Tubocapsenolide A directly targets and inhibits PLK1 to disrupt this specific damage‐clearance machinery. This blockade induces severe nucleolar stress and
Yueying Yang, Jing Liang, Lu Wang, Hongyan Zhang, Zhiruo Zhang, Yang Liu, Rui Zhu, Wen Xu, Shaohua Xu, Dejuan Sun, Ke Xiang, Yali Wang, Zhimin Fan, Zheng Wang, Hua Li, Lixia Chen   +15 more
wiley   +1 more source

ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study identifies ZMIZ2 as a therapeutic target for docetaxel‐resistant triple‐negative breast cancer, sustaining cancer stemness‐associated properties and docetaxel resistance. ZMIZ2 upregulation enhances DUX4‐mediated LGR5 activation through the SWI/SNF components BRG1 and BAF57.
Xueting Gan, Shulei Sun, Ran Hu, Yuheng Feng, Xinhao Wu, Fangqi Liu, Xuyong Lin, Xiupeng Zhang, Xuezhu Rong, Qiang Han   +9 more
wiley   +1 more source

PARP Research Notes

PARP Research ...
PARP Framework
core   +2 more sources

PARP inhibition preserves cone photoreceptors in rd2 retina

Acta Neuropathologica Communications
The rd2 mouse model, characterized by a mutation in the Prph2 gene, exhibits abnormal development of photoreceptor outer segments, resulting in progressive retinal degeneration. While the correlation between poly-ADP-ribose polymerase (PARP) activity and
Pakize Nur Akkaya, María Miranda, Inmaculada Almansa, Cigdem Elmas, Dragana Trifunovic, Zohreh Hosseinzadeh, Ayse Sahaboglu   +6 more
doaj   +1 more source

BRCA1 Mutation‐Recognizing Tetrahedral Framework Nucleic Acid Nanoplatform Enables Coordinated PARP/WEE1 Inhibition and STING‐Associated Antitumor Immunity in Ovarian Cancer

Advanced Science, EarlyView.
BRCA1 mutation‐responsive FBOA‐tFNA selectively recognizes mutant transcripts and coordinates reduction‐responsive intracellular delivery of olaparib and adavosertib, amplifying DNA damage and weakening G2/M checkpoint protection. These effects are accompanied by STING‐associated immune activation and stronger antitumor immunity, while sequential anti ...
Chenyi Wang, Mengying Yao, Jinhui Xie, Dingjie Wang, Yashi Shi, Xiaodan Mao, Chunhua Lu, Pengming Sun   +7 more
wiley   +1 more source

Targeting Mitochondrial Redox Signaling Promotes Neuroregeneration and Functional Recovery in a Multiple Sclerosis Model

Advanced Science, EarlyView.
Modulation of mitochondrial redox signaling by furapyrrodole activates CYB5R3 and suppresses Notch signaling, unlocking the regenerative potential of endogenous neural progenitor cells. This approach promotes neurogenesis, oligodendrogenesis, and remyelination, thereby improving neuronal function in a mouse model of multiple sclerosis and identifying ...
Yuki Narushima, Joshua Saylor, Shun Saito, Jinyan Zhou, Haruka Kawano, Shehata Anwar, Haruki Oba, Rachel Huezo, Miyu Okano, Haruki Matsuda, Makoto Kawatani, Kaori Honda, Hiroyuki Osada, Yuta Kikuchi, Masahito Ohue, Masami Ishibashi, Takayoshi Arai, Makoto Inoue, Midori A. Arai   +18 more
wiley   +1 more source

DTX3 Suppresses the NPM3–RUVBL1 Axis to Inhibit Homologous Recombination Repair and Abrogate Tumor Radioresistance

Advanced Science, EarlyView.
Deltex 3 (DTX3) catalyzes K27‐linked ubiquitination of nucleophosmin 3 to disrupt homologous recombination repair and reverse tumor radioresistance. Low DTX3 predicts poor survival and radiotherapy recurrence, serving as a radiosensitizing therapeutic target.
Jia‐Hao Xiao, Chang‐Jun Xie, Yan‐Hua Chen, Hao Cheng, Shuang‐Hui Li, Wei Li, Ya‐Wen Bin, Rui‐Min He, Ying‐Qing Li, Ping Feng   +9 more
wiley   +1 more source